The FDA has approved benralizumab (Fasenra) for the treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA). This is the second biologic approved for this rare disease, with the first being mepolizumab (Nucala) in 2017. Benralizumab is a monoclonal antibody targeting eosinophils and has shown positive results in a noninferiority trial compared to mepolizumab. It is administered via subcutaneous injection every 4 weeks initially, then every 8 weeks. Common side effects include headache and pharyngitis. The approval of benralizumab offers a much-needed treatment option for EGPA patients, as it can help achieve remission and potentially reduce the need for long-term steroid therapy.
Source link
FDA Approves Benralizumab for EGPA Vasculitis Indication
